Marked Response to Single Agent Trastuzumab in a Patient with Metastatic HER-2 Gene Amplified Rectal Cancer

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cancer Investigation

• Publication date

  2011-07-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/07357907.2011.590569PMID 21696295
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial.

  2016cited by this paper
• Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL).

  2010cited by this paper
• Relationship between NFKB1 -94 insertion/deletion ATTG polymorphism and susceptibility of cervical squamous cell carcinoma risk.

  2010cited by this paper
• Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).

  2009cited by this paper
• Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

  2009cited by this paper
• Gastrosplenic fistula from Hodgkin's lymphoma.

  2009cited by this paper
• Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).

  2009cited by this paper
• Colorectal hepatic metastases: adjuvant chemotherapy and survival.

  2009cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial

  2004cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions

  2025cites this paper
• Clinical Trial Outcomes: What Matters to Patients.

  2019cites this paper
• Future Therapies in Medical Oncology

  2018cites this paper
• FGFR2 amplification in colorectal adenocarcinoma

  2017cites this paper
• Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer.

  2017cites this paper
• Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine

  2017cites this paper
• Immunohistochemical Study of HER2/neu Expression in Colorectal Cancer and its Relation to other Clinicopathological Criteria and Prognostic Factors

  2017cites this paper
• Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

  2016cites this paper
• HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib

  2016cites this paper
• Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites

  2015cites this paper
• Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification

  2015cites this paper
• Monitoring Trastuzumab Resistance and Cardiotoxicity: A Tale of Personalized Medicine.

  2015cites this paper
• Current and Future Approaches to Target the Epidermal Growth Factor Receptor and Its Downstream Signaling in Metastatic Colorectal Cancer.

  2015cites this paper
• Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.

  2015cites this paper
• Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

  2015cites this paper
• HER-2 overexpression and survival in colorectal cancer: a meta-analysis

  2014cites this paper
• HER2 in solid tumors: more than 10 years under the microscope; where are we now?

  2014cites this paper
• Clinical Trial Outcomes part of HER 2 / neu : an increasingly important therapeutic target . Part 3 : clinical applications and investigations

  2014cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations

  2014cites this paper
• FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival

  2014cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

  2014cites this paper
• Marqueurs de réponse aux thérapies ciblées et personnalisation thérapeutique dans les cancers colorectaux métastatiques

  2014cites this paper
• Part 2 : Distribution of HER 2 / neu overexpression and gene amplification by organ , tumor site and histology

  2014cites this paper
• Prognostic significance and targeting of HER family in colorectal cancer.

  2013cites this paper
• Association of human epidermal growth factor receptor-2 expression and clinicopathological findings in patients with colorectal cancer.

  2012cites this paper
• Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location.

  2012cites this paper
• Dual-Labeling Strategies for Nuclear and Fluorescence Molecular Imaging: A Review and Analysis

  2011cites this paper